STOCK TITAN

Aspen Technology Appoints David Leitham as Senior Vice President and General Manager to Lead Pharmaceutical Industry Effort

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary

Aspen Technology, Inc. (NASDAQ:AZPN) has appointed David Leitham as Senior Vice President and General Manager to spearhead its growth strategy within the pharmaceutical sector. With over 25 years of experience in the pharmaceutical industry, Leitham aims to expand AspenTech's market presence and drive product strategy. Previously, he led double-digit growth in software revenue at Thermo Fisher Scientific and has a strong background in mergers and acquisitions. CEO Antonio Pietri underscores the importance of this leadership change for advancing operational excellence in the industry.

Positive
  • David Leitham brings 25 years of pharmaceutical industry experience.
  • Proven track record of achieving double-digit growth in software revenue.
  • Focus on expanding AspenTech's footprint in the pharmaceutical market.
Negative
  • Concerns about continuity during leadership transition.

Aspen Technology, Inc. (NASDAQ:AZPN), a global leader in asset optimization software, has appointed David Leitham as Senior Vice President and General Manager to lead the company’s pharmaceutical industry growth strategy.

David Leitham, Senior Vice President and General Manager at Aspen Technology (Photo: Business Wire)

David Leitham, Senior Vice President and General Manager at Aspen Technology (Photo: Business Wire)

Leitham has 25 years’ experience in the pharmaceutical industry and is responsible for expanding AspenTech’s footprint in the pharmaceuticals market, shaping the product and solution strategy and leading go-to-market efforts. He has demonstrated a track record of success integrating and transforming software businesses and products and growing them at double digits, while leading a software portfolio that drove over one billion dollars in connected sales. He brings significant expertise to AspenTech in mergers and acquisitions integration having worked on multiple integration efforts to transform businesses into high performing operations.

Leitham joins AspenTech from Thermo Fisher Scientific, where he was Vice President and General Manager responsible for a team that consistently delivered double-digit growth in software revenue. He also held roles at GlaxoSmithKline, where he served as Vice President, Information Engineering, Technology and Architecture; The Network Connection, where he served as Vice President, Software Engineering and Vice President, Application Development; and FAAC Incorporated, where he held several engineering positions.

“We believe that the pharmaceutical industry can continue to benefit from AspenTech’s current solution portfolio as it increases focus on operational excellence and accelerates its digitalization journey in manufacturing and across the enterprise. We see a significant opportunity to contribute to compliance with the regulatory requirements pharmaceutical companies must meet and to the value creation opportunities available through their ongoing digitalization efforts. Bringing David on board is an important step in helping them achieve these important objectives,” said Antonio Pietri, President and Chief Executive Officer of AspenTech.

“AspenTech has an unrivaled reputation in the process manufacturing industries,” said Leitham. “That reputation has been earned through a relentless focus on meeting the needs of its customers, which I have long shared, and I am looking forward to enhancing that approach, along with our technology and expertise, to the pharmaceutical industry.”

About Aspen Technology

Aspen Technology (AspenTech) is a global leader in asset optimization software. Its solutions address complex, industrial environments where it is critical to optimize the asset design, operation and maintenance lifecycle. AspenTech uniquely combines decades of process modelling expertise with artificial intelligence. Its purpose-built software platform automates knowledge work and builds sustainable competitive advantage by delivering high returns over the entire asset lifecycle. As a result, companies in capital-intensive industries can maximize uptime and push the limits of performance, running their assets safer, greener, longer and faster. Visit AspenTech.com to find out more.

© 2021 Aspen Technology, Inc. AspenTech and the Aspen leaf logo are trademarks of Aspen Technology, Inc.

FAQ

Who is David Leitham and what is his role at Aspen Technology?

David Leitham is the new Senior Vice President and General Manager at Aspen Technology, focusing on the company's pharmaceutical industry growth strategy.

What experience does David Leitham bring to Aspen Technology?

Leitham has over 25 years of experience in the pharmaceutical industry, having held senior roles at Thermo Fisher Scientific and GlaxoSmithKline, and is known for achieving double-digit growth.

How will David Leitham's appointment impact Aspen Technology's strategy?

His appointment is expected to enhance AspenTech's strategy in the pharmaceutical sector, targeting operational excellence and digitalization.

What is Aspen Technology's focus in the pharmaceutical industry?

Aspen Technology aims to contribute to compliance with regulatory requirements and enhance value creation through digitalization efforts in the pharmaceutical sector.

Aspen Technology Inc

NASDAQ:AZPN

AZPN Rankings

AZPN Latest News

AZPN Stock Data

15.81B
26.77M
57.68%
48.49%
2.14%
Software - Application
Services-computer Programming Services
Link
United States of America
BEDFORD